3-(乙酰氨基甲基)嘧啶 | 22977-34-0

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-(乙酰氨基甲基)嘧啶
• 中文别名: N1-(3-吡啶甲基)乙酰胺；2-乙酰胺基吡啶；3-(乙酰氨基甲基)吡啶
• 英文名称: N-(pyridin-3-ylmethyl)acetamide
• 英文别名: 3-(Acetamidomethyl)pyridine
• CAS: 22977-34-0
• 化学式: C₈H₁₀N₂O
• mdl: MFCD00495392
• 分子量: 150.18
• InChiKey: KQZCRXVJXGYIFM-UHFFFAOYSA-N

物化性质

• 沸点：
  152 °C
• 密度：
  1.088±0.06 g/cm3(Predicted)
• 闪点：
  152-154°C/0.8mm
• 稳定性/保质期：

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 储存条件：
  <p><br></p>

SDS

Name:	N1-3-(Pyridylmethyl)acetamide Material Safety Data Sheet
Synonym:	None know
CAS:	22977-34-0

Section 1 - Chemical Product MSDS Name:N1-3-(Pyridylmethyl)acetamide Material Safety Data Sheet
Synonym:None know

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
22977-34-0	N1-3-(Pyridylmethyl)acetamide	97+%	unlisted

Hazard Symbols: XN
Risk Phrases: 22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Causes respiratory tract irritation.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Vacuum or sweep up material and place into a suitable disposal container. Avoid runoff into storm sewers and ditches which lead to waterways.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 22977-34-0: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid or liquid
Color: Off White
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 152 - 154 deg C @0.8mm Hg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H10N2O
Molecular Weight: 150.18

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 22977-34-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
N1-3-(Pyridylmethyl)acetamide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 22 Harmful if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 22977-34-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 22977-34-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 22977-34-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

合成制备方法

---

用途

---

反应信息

• 作为反应物：
  描述：

  3-(乙酰氨基甲基)嘧啶 在 palladium on activated charcoal 盐酸 、 sodium tetrahydroborate 、 氢气 作用下， 以 甲醇 、 乙醇 、 水 、 甲苯 为溶剂， 反应 30.0h， 生成 1-苄基哌啶-3-甲胺
  参考文献：
  名称：

  Synthesis and Structure-Activity Relationships of 4-Amino-5-chloro-2-ethoxybenzamides with Six- and Seven-Membered Heteroalicycles as Potential Gastroprokinetic Agents.

  摘要：

  一系列新型4-氨基-5-氯-2-乙氧基苯酰胺3b-f和含有六元和七元杂环的化合物5-8被制备并评估了其胃促动活性。通过将4-氨基-N-[(4-苄基-2-吗啉基)甲基]-5-氯-2-乙氧基苯酰胺（3a）中的吗啉氧替换为其他原子（硫、氮和碳）得到的化合物3b-e，一般显示出强效的胃排空活性。N-(4-苄基-3-吗啉基)甲基苯酰胺（5a）及其类似物5b-e活性较弱。然而，N-(4-苄基-3-吗啉基)ethyl苯酰胺8的活性与3a相当。含有七元杂环的苯酰胺6a-e显示出相当强的活性。通过计算机图形学进行的5a、6a和8相对于3a的分子重叠分析表明，N-苄基取代基的方向对胃排空活性影响重大，而杂环氮的位置影响较小。

  DOI：

  10.1248/cpb.43.1137
• 作为产物：
  描述：

  3-氨甲基吡啶 在 吡啶 、 4-二甲氨基吡啶 、 乙酸酐 作用下， 生成 3-(乙酰氨基甲基)嘧啶
  参考文献：
  名称：

  Pyridinium compounds which are useful as antagonists of platelet

  摘要：

  这项发明是有机芳基、酰胺、亚胺和碳酸酯吡啶拮抗剂，用于抑制血小板活化因子。

  公开号：

  US05208247A1
• 作为试剂：
  描述：

  3-氨甲基吡啶 、 乙酸酐 在 4-二甲氨基吡啶 3-(乙酰氨基甲基)嘧啶 、 silica gel 、 甲醇乙酸乙酯 作用下， 以 吡啶 为溶剂， 以to give 31.8 g of the desired product as a yellow oil的产率得到3-(乙酰氨基甲基)嘧啶
  参考文献：
  名称：

  Pyridinium compounds which are useful as antagonists of platelet

  摘要：

  这项发明是关于芳基、酰胺、亚酰胺和氨基甲酸酯吡啶对血小板活化因子的拮抗剂。

  公开号：

  US05208247A1

文献信息

• [EN] SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS<br/>[FR] ANALOGUES D'URÉE PONTÉS SUBSTITUÉS EN TANT QUE MODULATEURS DE SIRTUINE
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2016079709A1

  公开（公告）日：2016-05-26

  The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.

  本发明涉及一种新型的取代桥式脲类似物化合物，其化学式为（I）或其药学上可接受的盐，相应的药物组合物，制备这种化合物的方法以及单独使用或与其他治疗剂联合使用的这些化合物作为Sirtuin调节剂，可用于增加细胞寿命，并用于治疗和/或预防各种疾病和紊乱，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块紊乱、炎症、癌症和/或潮红有关的疾病或紊乱，以及那些会受益于增加线粒体活性的疾病或紊乱。
• [EN] 2,3-DISUBSTITUTED 1 -ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS<br/>[FR] DÉRIVÉS 2,3-DISUBSTITUÉS DE 1-ACYL-4-AMINO-1,2,3,4-TÉTRAHYDROQUINOLÉINE ET LEUR UTILISATION COMME INHIBITEURS DE BROMODOMAINES
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2014140076A1

  公开（公告）日：2014-09-18

  The present invention relates to novel compounds of formula (I), wherein R1 is C1-4alkyl; R2 is C1-4alkyl, C3-7cycloalkyl, -CH2CF3, -CH2OCH3 or heterocyclyl; R3 is C1-4alkyl, -CH2F, -CH2OH or -CH2O(O)CH3; R4 when present is as defined in claim 1; R5 when present is H, halo, hydroxy or C1-6alkoxy; A is -NH-, -O-, -S-, -SO-, -SO2-, -N(C1-4alkyl)- or -NC(O)(CH3)-; V is phenyl, heteroaromatic or pyridone any of which may be optionally substituted by 1, 2 or 3 substituents; W is CH or N; X is C or N; Y is C or N; and Z is CH or N; subject to the proviso that no more than 2 of W, X, Y and Z are N, pharmaceutical compositions containing such compounds and to their use as bromodomain inhibitors.

  本发明涉及式(I)的新化合物，其中R1为C1-4烷基；R2为C1-4烷基、C3-7环烷基、-CH2CF3、- 或杂环烷基；R3为C1-4烷基、-CH2F、- H或-CH2O(O)CH3；R4存在时如权利要求1所定义；R5存在时为H、卤素、羟基或C1-6烷氧基；A为-NH-、-O-、-S-、-SO-、-SO2-、-N(C1-4烷基)-或-NC(O)( )-；V为苯基、杂芳基或吡啶酮，其中任何一个可以选择性地被1、2或3个取代基取代；W为CH或N；X为C或N；Y为C或N；Z为CH或N；但W、X、Y和Z中不超过2个为N，含有这种化合物的药物组合物以及它们作为溴结构域抑制剂的用途。
• HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS
  申请人：CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD.

  公开号：US20170253614A1

  公开（公告）日：2017-09-07

  A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.

  一系列丙型肝炎病毒（HCV）抑制剂及其组合物，以及在制备用于治疗慢性HCV感染的药物时的应用。特别是一系列用作NS5A抑制剂的化合物，以及在药物制剂中的组合物和用途。
• Manganese-Catalyzed Direct Conversion of Ester to Amide with Liberation of H₂
  作者：Akash Mondal、Murugan Subaramanian、Avanashiappan Nandakumar、Ekambaram Balaraman

  DOI：10.1021/acs.orglett.8b01305

  日期：2018.6.1

  A simple and efficient Mn-catalyzed acylation of amines is achieved using both acyl and alkoxy functions of unactivated esters with the liberation of molecular hydrogen as a sole byproduct. The present protocol provides an atom-economical and sustainable route for the synthesis of amides from esters by employing an earth-abundant manganese salt and inexpensive phosphine-free tridentate ligand.

  使用未活化的酯的酰基和烷氧基官能团，同时释放分子氢作为唯一的副产物，可实现胺的简单有效的Mn催化酰化反应。本方案提供了一种原子经济且可持续的途径，可通过使用富含地球的锰盐和廉价的不含膦的三齿配体从酯合成酰胺。
• [EN] HETEROARYL COMPOUNDS AS PDE10A INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROARYLE EN TANT QU'INHIBITEURS DE LA PDE 10A
  申请人：GLENMARK PHARMACEUTICAL S A

  公开号：WO2011132048A1

  公开（公告）日：2011-10-27

  The present invention provides heteroaryl compounds as Phosphodiesterase 10A (PDE I OA) inhibitors. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders by inhibiting Phosphodiesterase 10A enzyme. Also provided herein are processes for preparing compounds described herein, Formula (I), intermediates used in their synthesis, pharmaceutical compositions thereof.

  本发明提供了杂环芳基化合物作为磷酸二酯酶10A（PDE10A）抑制剂。具体来说，本文描述的化合物可用于通过抑制磷酸二酯酶10A酶来治疗或预防疾病、症状和/或疾病。本文还提供了制备本文描述的化合物、式（I）、用于它们合成的中间体以及其制药组合物的方法。